Archives

  • FRISQ’s Interim Report Q2, 2021

    CEO StatementFRISQ’s Capital Markets Day in May was a great opportunity to present where we are and where we are moving to. We could then, and can now, report that higher recurring revenues have had a positive effect on cash flow, along with a cost control that has shifted funds from administration to development and …

    More
  • Interim Report Q1, 2021 – Turnover exceeding previous full year

    CEO Statement The pandemic continues to affect our industry in many ways. But although the room for long-term digitalisation decisions is small right now, FRISQ’s pilot projects continue to run as planned or better. Our clients’ innovation continue to depend heavily on FRISQ Care and we have in several instances been asked to increase our …

    More
  • Report Q4 and Full Year 2020

    January-December 2020 CEO Statement For us who work in the healthcare sector, the fourth quarter of 2020 was characterized as much by the global pandemic as previous quarters; In fact, almost more so since we have unfortunately been hit by a second corona wave before commencing large-scale vaccinations. It is a worrying situation for the …

    More
  • Interim Report Q3, 2020

    CEO StatementAs we’re closing a busy quarter for FRISQ I’m proud to say we’ve carried out a fully subscribed, directed share issue of 78.75 million SEK. This capital infusion will strengthen our sales and implementation efforts in 2021. While we work hard to develop a product that drives both better health outcomes and patient engagement, …

    More
  • Interim Report Q1, 2020

    CEO statementIt is a privilege for me today to present my first quarter and FRISQ’s second quarterly results for 2020. The ongoing pandemic has presented great challenges for a healthcare sector that, by necessity, has been forced to prioritize emergency care – repeatedly straining old-fashioned tools and methods to, and beyond, the limit – over improvements …

    More
  • Interim Report Q1, 2020

    Federal stamp of approval creates opportunities in a turbulent time. FRISQ – the only digital solution that meets the requirements for the patient contract CEO statementDuring the first three months of the year we conducted an over-subscribed preferential rights issue of approximately 74.6 MSEK, as well as many business development initiatives with customers in Sweden …

    More
No products in the cart.